Consumerization is beginning to reshape how patients discover, evaluate and access branded prescription medicines in the US. Starting with obesity, this talk will take a practical look at the potential or actual direct-to-patient market, where this consumer-led demand may head next and how commercial teams should get ahead of it.
The rise of cash-pay consumerization in US Pharma, powered by TrumpRx and direct-to-patient channels
Obesity as the leading example
Which categories are next, and what it means for commercial strategy
